Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 2/20 | 0.44 |
| ▸ | PDE6D | O43924 | 1/20 | 0.44 |
| ▸ | PDE6A | P16499 | 1/20 | 0.44 |
| ▸ | PDE6G | P18545 | 1/20 | 0.44 |
| ▸ | PDE6B | P35913 | 1/20 | 0.44 |
| ▸ | PDE6C | P51160 | 1/20 | 0.44 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23575736 | 0.87 | PDE4B (0.49) | GAARXFP1NPSR1MAPK1MAPT | |
| SCHEMBL23575691 | 0.86 | MAPT (0.57) | GAARXFP1MAPTTP53AURKB | |
| SCHEMBL18530485 | 0.85 | KDM4E (0.44) | GAARXFP1NPSR1MAPK1MAPT | |
| SCHEMBL23575679 | 0.85 | MAPK1 (0.52) | GAARXFP1NPSR1MAPK1MAPT | |
| SCHEMBL18530521 | 0.84 | KMT2A (0.45) | GAARXFP1NPSR1MAPK1MAPT | |
| SCHEMBL23575227 | 0.84 | EGFR (0.41) | TP53PKM | |
| SCHEMBL23575251 | 0.83 | PDE4B (0.44) | GAARXFP1NPSR1MAPK1MAPT | |
| SCHEMBL23575685 | 0.82 | MAPT (0.55) | GAARXFP1NPSR1MAPK1MAPT | |
| SCHEMBL23575695 | 0.79 | JAK3 (0.42) | GAARXFP1NPSR1MAPK1MAPT | |
| SCHEMBL23234973 | 0.78 | MAPK1 (0.76) | GAARXFP1NPSR1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3846800-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | RBBP9, MTHFD1, BRWD1 | GAA 1619/4885RXFP1 4025/4885NPSR1 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.